Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.64 |
| ▸ | MERTK | Q12866 | 9/20 | 0.43 |
| ▸ | AXL | P30530 | 7/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591350 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3MERTKAXLMET | |
| SCHEMBL4669197 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3MERTKAXLMET | |
| SCHEMBL3257520 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3MERTKAXLMET | |
| SCHEMBL589606 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3MERTKAXLMET | |
| SCHEMBL590519 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3MERTKAXLMET | |
| SCHEMBL4367305 | 0.84 | ADORA2A (0.60) | ADORA2AADORA3 | |
| SCHEMBL590421 | 0.84 | ADORA2A (0.60) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL588605 | 0.80 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL591104 | 0.78 | ADORA2A (1.00) | ADORA2AADORA3ADORA1 | |
| Trifluoroacetic Acid SCHEMBL589376 | 0.77 | ADORA2A (0.68) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885MERTK 2426/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885MERTK 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.